
Drugs like Ozempic and Wegovy have had a meteoric rise in recent years, with benefits like weight loss and help with other health issues. But according to a recent study, those benefits fade within two years of patients stopping their treatment.
According to a study published in the BMJ, data from 9,341 obese or overweight patients treated in 37 studies with any of 18 different weight-loss drugs showed that they regained about one pound on average after stopping the drugs.
The same study said they were projected to return to their pre-treatment weight in about two years.
But weight was not the only thing that was projected to return after stopping the treatment. According to the same study, health risk factors like blood pressure and cholesterol levels, which saw benefits while taking the drugs, were projected to return to their old levels within 1.4 years.
GLP-1 medications tested as well
About half of the patients studied took newer GLP-1 drugs like semaglutide, sold as Ozempic and Wegovy, as well as tirzepatide, which is sold as Mounjaro and Zepbound. According to the study, the weight regain rate was faster for these drugs, with an average of 1.8 pounds per month.
“But because people on semaglutide or tirzepatide lose more weight in the first place, they all end up returning to baseline at approximately the same time,” study senior researcher Dimitrios Koutoukidis of Oxford University told Reuters.
Weight loss drugs have shown some success
Weight loss drugs like the ones tested in the study have shown large levels of success in the United States in recent years. Back in October 2025, a survey from the Gallup National Health and Well-Being Index showed that there were an estimated 7.6 million fewer obese people in the United States compared to 2022.
In 2022, the U.S. adult obesity rate was a record-high 39.9%, while in 2025, that rate gradually declined to 37%. While the obesity rate dropped, the usage of GLP-1 drugs like Ozempic and Wegovy doubled between 2025 and 2024, according to the same study.
Contributing: Nicole Fallert, USA TODAY; Reuters
Fernando Cervantes Jr. is a trending news reporter for USA TODAY. Reach him at [email protected] and follow him on X @fern_cerv_.
This article originally appeared on USA TODAY: Here's how fast you can gain weight after ending GLP-1, per study
LATEST POSTS
- 1
Iran warns its ready to open new front in Yemen, close Bab al-Mandab Strait with Houthis - 2
Who is Artemis? Meet the Greek goddess who inspired NASA's return to the moon - 3
Opening Monetary Information: Your Exhaustive Manual for Finding out about Individual budget - 4
2024's Hot Games: Must-Play Titles of the Year - 5
The most effective method to Refresh the Infotainment Framework in the Volvo XC40
Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
4 Energy-Proficient Clothes washers to Consider in 2024
Vote in favor of your Favored kind of craftsmanship
Russia Establishing Long-Range Drone Bases In Belarus, Warns Ukraine
Emergent Cold LatAm opens state-of-the-art cold storage hub in Guadalajara
This widow influencer is using jokes to cope after her husband's death. It's OK if people don't get it.
Research institutions tout the value of scholarship that crosses disciplines – but academia pushes interdisciplinary researchers out
FDA updates risk classification for voluntary shredded cheese recall
Step by step instructions to Buy a Jeep Wrangler on a Senior's Spending plan












